Drug Facts
Composition & Profile
Identifiers & Packaging
HOW SUPPLIED Sodium Acetate Injection, USP 40 mEq (2 mEq/mL) is supplied as follows: Unit of Sale Concentration Each NDC 0409-7299-73 40 mEq/20 mL NDC 0409-7299-83 Tray Containing 25 Units (2 mEq/mL) Single-dose Fliptop Vial Each vial is partially filled to provide air space for complete vacuum withdrawal of the contents into the intravenous container. Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Distributed by Hospira, Inc. Lake Forest, IL 60045 USA LAB-0890-3.0 01/2018 Logo; PRINCIPAL DISPLAY PANEL - 20 mL Vial Label 20 mL Single-dose SODIUM ACETATE Injection, USP Rx only 40 mEq/20 mL (2 mEq/mL) CAUTION: MUST BE DILUTED For Intravenous Use Dist. by Hospira, Inc., Lake Forest, IL 60045 USA PRINCIPAL DISPLAY PANEL - 20 mL Vial Label; PRINCIPAL DISPLAY PANEL - 20 mL Vial Tray 20 mL Single-dose Rx only 25 Units/ NDC 0409-7299-73 SODIUM ACETATE Injection, USP 40 mEq/20 mL (2 mEq/mL) For Intravenous Use CAUTION: MUST BE DILUTED Hospira PRINCIPAL DISPLAY PANEL - 20 mL Vial Tray
- HOW SUPPLIED Sodium Acetate Injection, USP 40 mEq (2 mEq/mL) is supplied as follows: Unit of Sale Concentration Each NDC 0409-7299-73 40 mEq/20 mL NDC 0409-7299-83 Tray Containing 25 Units (2 mEq/mL) Single-dose Fliptop Vial Each vial is partially filled to provide air space for complete vacuum withdrawal of the contents into the intravenous container. Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Distributed by Hospira, Inc. Lake Forest, IL 60045 USA LAB-0890-3.0 01/2018 Logo
- PRINCIPAL DISPLAY PANEL - 20 mL Vial Label 20 mL Single-dose SODIUM ACETATE Injection, USP Rx only 40 mEq/20 mL (2 mEq/mL) CAUTION: MUST BE DILUTED For Intravenous Use Dist. by Hospira, Inc., Lake Forest, IL 60045 USA PRINCIPAL DISPLAY PANEL - 20 mL Vial Label
- PRINCIPAL DISPLAY PANEL - 20 mL Vial Tray 20 mL Single-dose Rx only 25 Units/ NDC 0409-7299-73 SODIUM ACETATE Injection, USP 40 mEq/20 mL (2 mEq/mL) For Intravenous Use CAUTION: MUST BE DILUTED Hospira PRINCIPAL DISPLAY PANEL - 20 mL Vial Tray
Overview
Sodium Acetate Injection, USP 40 mEq (2 mEq/mL) is a sterile, nonpyrogenic, concentrated solution of sodium acetate in water for injection. The solution is administered, after dilution, by the intravenous route as an electrolyte replenisher. It must not be administered undiluted. Each 20 mL contains 3.28 g of sodium acetate (anhydrous) which provides 40 mEq each of sodium (Na + ) and acetate (CH 3 COO − ). The solution contains no bacteriostat, antimicrobial agent or added buffer. May contain acetic acid for pH adjustment; the pH is 6.5 (6.0 to 7.0). The osmolar concentration is 4 mOsmol/mL (calc). The solution is intended as an alternative to sodium chloride to provide sodium ion (Na + ) for addition to large volume infusion fluids for intravenous use. Sodium Acetate, USP (anhydrous) is chemically designated CH 3 COONa, a hygroscopic powder very soluble in water. The semi-rigid container is fabricated from a specially formulated polyolefin. It is a copolymer of ethylene and propylene. The safety of the plastic has been confirmed by tests in animals according to USP biological standards for plastic containers. The container requires no vapor barrier to maintain the proper drug concentration.
Indications & Usage
Sodium Acetate Injection, USP 40 mEq is indicated as a source of sodium, for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.
Dosage & Administration
Sodium Acetate Injection, USP 40 mEq is administered intravenously only after dilution in a larger volume of fluid . The dose and rate of administration are dependent upon the individual needs of the patient. Serum sodium should be monitored as a guide to dosage. Using aseptic technique, all or part of the contents of one or more vials may be added to other intravenous fluids to provide any desired number of milliequivalents (mEq) of sodium (Na + ) with an equal number of acetate (CH 3 COO − ). Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. See PRECAUTIONS.
Warnings & Precautions
WARNINGS Sodium Acetate Injection, USP 40 mEq must be diluted before use. To avoid sodium overload and water retention, infuse sodium-containing solutions slowly. Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention. In patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention. Solutions containing acetate ions should be used with great care in patients with metabolic or respiratory alkalosis. Acetate should be administered with great care in those conditions in which there is an increased level or an impaired utilization of this ion, such as severe hepatic insufficiency. The intravenous administration of this solution (after appropriate dilution) can cause fluid and/or solute overloading resulting in dilution of other serum electrolyte concentrations, overhydration, congested states or pulmonary edema. Excessive administration of potassium free solutions may result in significant hypokalemia. WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
Contraindications
Sodium Acetate Injection, USP 40 mEq is contraindicated in patients with hypernatremia or fluid retention.
Adverse Reactions
Sodium overload can occur with intravenous infusion of excessive amounts of sodium-containing solutions. See WARNINGS and PRECAUTIONS.
Similar Drugs
Related medications based on brand, generic name, substance, active ingredients.